BACKGROUND: In chronic lymphocytic leukemia (CLL), changes in the peripheral blood lymphocyte subsets play an important role in disease progression and infectious complications. The impact of chemoimmunotherapy (CIT) on these changes has not been extensively studied METHODS: We used multi-color flow cytometry, to prospectively measure absolute and relative numbers of CD4+ and CD8+ T-cells and their subsets in 45 patients with indolent untreated CLL, 86 patients indicated for first-line treatment, and 34 healthy controls. In 55 patients, we analyzed the impact of CIT RESULTS: CLL patients had a significant increase in most cell populations in comparison to controls. Progression of CLL was characterized by significantly elevated counts with the exception of a lower percentage of naïve T-cells. After treatment, the percentage of naïve T-cells further decreased at the expense of effector memory T-cells (TEM). In patients with indolent CLL, higher percentages of naïve CD4+ (p = 0.0026) and naïve CD8+ (p = 0.023) T-cells were associated with a longer time to first treatment (TTFT). The elevation of CD4+ central memory T-cells (TCM) (p = 0.27) and TEM (p = 0.003) counts and a higher percentage of CD4+ TEM (p = 0.0047), were linked with shorter TTFT. In treated patients, increased regulatory T-cells count was associated with shorter time to next treatment (TTNT) (p = 0.042), while higher CD4+ TCM count with shorter TTNT (p = 0.035) and shorter overall survival (p = 0.041). CONCLUSION: Our results indicate that naïve cell depletion and CD4+ TCM and TEM increases are detrimental to CLL patients' prognosis.

4th Department of Internal Medicine Hematology Faculty of Medicine University Hospital and Charles University Hradec Kralove Czech Republic

Institute of Clinical Immunology and Allergology Faculty of Medicine University Hospital and Charles University Hradec Kralove Czech Republic

Zobrazit více v PubMed

Palmer S, Hanson CA, Zent CS, et al. Prognostic importance of T and NK‐cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol. 2008;141(5):607‐614. doi:10.1111/j.1365-2141.2008.07070.x PubMed DOI PMC

Nunes C, Wong R, Mason M, Fegan C, Man S, Pepper C. Expansion of a CD8(+)PD‐1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression [published correction appears in Clin cancer res. 2012 Jul 1;18(13):3714]. Clin Cancer Res. 2012;18(3):678‐687. doi:10.1158/1078-0432.CCR-11-2630 PubMed DOI

Wu J, Xu X, Lee EJ, et al. Phenotypic alteration of CD8+ T cells in chronic lymphocytic leukemia is associated with epigenetic reprogramming. Oncotarget. 2016;7(26):40558‐40570. doi:10.18632/oncotarget.9941 PubMed DOI PMC

Brusa D, Serra S, Coscia M, et al. The PD‐1/PD‐L1 axis contributes to T‐cell dysfunction in chronic lymphocytic leukemia. Haematologica. 2013;98(6):953‐963. doi:10.3324/haematol.2012.077537 PubMed DOI PMC

Gonnord P, Costa M, Abreu A, et al. Multiparametric analysis of CD8+ T cell compartment phenotype in chronic lymphocytic leukemia reveals a signature associated with progression toward therapy. Onco Targets Ther. 2019;8(4):e1570774. doi:10.1080/2162402X.2019.1570774 PubMed DOI PMC

Piper KP, Karanth M, McLarnon A, et al. Chronic lymphocytic leukaemia cells drive the global CD4+ T cell repertoire towards a regulatory phenotype and leads to the accumulation of CD4+ forkhead box P3+ T cells. Clin Exp Immunol. 2011;166(2):154‐163. doi:10.1111/j.1365-2249.2011.04466.x PubMed DOI PMC

Lad DP, Varma S, Varma N, Sachdeva MU, Bose P, Malhotra P. Regulatory T‐cells in B‐cell chronic lymphocytic leukemia: their role in disease progression and autoimmune cytopenias. Leuk Lymphoma. 2013;54(5):1012‐1019. doi:10.3109/10428194.2012.728287 PubMed DOI

Jadidi‐Niaragh F, Yousefi M, Memarian A, et al. Increased frequency of CD8+ and CD4+ regulatory T cells in chronic lymphocytic leukemia: association with disease progression. Cancer Invest. 2013;31(2):121‐131. doi:10.3109/07357907.2012.756110 PubMed DOI

Mpakou VE, Ioannidou HD, Konsta E, et al. Quantitative and qualitative analysis of regulatory T cells in B cell chronic lymphocytic leukemia. Leuk Res. 2017;60:74‐81. doi:10.1016/j.leukres.2017.07.004 PubMed DOI

Weiss L, Melchardt T, Egle A, Grabmer C, Greil R, Tinhofer I. Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. Cancer. 2011;117(10):2163‐2169. doi:10.1002/cncr.25752 PubMed DOI

D'Arena G, D'Auria F, Simeon V, et al. A shorter time to the first treatment may be predicted by the absolute number of regulatory T‐cells in patients with rai stage 0 chronic lymphocytic leukemia. Am J Hematol. 2012;87(6):628‐631. doi:10.1002/ajh.23170 PubMed DOI

Dasgupta A, Mahapatra M, Saxena R. A study for proposal of use of regulatory T cells as a prognostic marker and establishing an optimal threshold level for their expression in chronic lymphocytic leukemia. Leuk Lymphoma. 2015;56(6):1831‐1838. doi:10.3109/10428194.2014.966245 PubMed DOI

Wang WT, Zhu HY, Wu YJ, et al. Elevated absolute NK cell counts in peripheral blood predict good prognosis in chronic lymphocytic leukemia. J Cancer Res Clin Oncol. 2018;144(3):449‐457. doi:10.1007/s00432-017-2568-2 PubMed DOI

Jadidi‐Niaragh F, Jeddi‐Tehrani M, Ansaripour B, Razavi SM, Sharifian RA, Shokri F. Reduced frequency of NKT‐like cells in patients with progressive chronic lymphocytic leukemia. Med Oncol. 2012;29(5):3561‐3569. doi:10.1007/s12032-012-0262-4 PubMed DOI

Wadhwa PD, Morrison VA. Infectious complications of chronic lymphocytic leukemia. Semin Oncol. 2006;33(2):240‐249. doi:10.1053/j.seminoncol.2005.12.013 PubMed DOI

Koch S, Larbi A, Derhovanessian E, Ozcelik D, Naumova E, Pawelec G. Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people. Immun Ageing. 2008;5:6. doi:10.1186/1742-4933-5-6 PubMed DOI PMC

Romero P, Zippelius A, Kurth I, et al. Four functionally distinct populations of human effector‐memory CD8+ T lymphocytes. J Immunol. 2007;178(7):4112‐4119. doi:10.4049/jimmunol.178.7.4112 PubMed DOI

Smolej L, Vodárek P, Écsiová D, Šimkovič M. Chemoimmunotherapy in the first‐line treatment of chronic lymphocytic Leukaemia: dead yet, or alive and kicking? Cancers (Basel). 2021;13(13):3134. doi:10.3390/cancers13133134 PubMed DOI PMC

Gauthier M, Durrieu F, Martin E, et al. Prognostic role of CD4 T‐cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia. BMC Cancer. 2019;19(1):809. doi:10.1186/s12885-019-5971-z PubMed DOI PMC

Ysebaert L, Gross E, Kühlein E, et al. Immune recovery after fludarabine‐cyclophosphamide‐rituximab treatment in B‐chronic lymphocytic leukemia: implication for maintenance immunotherapy. Leukemia. 2010;24(7):1310‐1316. doi:10.1038/leu.2010.89 PubMed DOI

Egle A, Weiss L, Gassner F, et al. Minimal residual disease (MRD) and T/NK cell dynamics during Fludarabine, cyclophosphamide plus rituximab (FCR) followed by Fludarabine plus rituximab (FR) and remission maintenance therapy with rituximab in previously untreated B‐chronic lymphocytic leukemia (B‐CLL): risk factor stratification in the Chairos study. Blood. 2008;112(11):1089. doi:10.1182/blood.V112.11.3175.3175 DOI

Martínez‐Calle N, Hartley S, Ahearne M, et al. Kinetics of T‐cell subset reconstitution following treatment with bendamustine and rituximab for low‐grade lymphoproliferative disease: a population‐based analysis. Br J Haematol. 2019;184(6):957‐968. doi:10.1111/bjh.15722 PubMed DOI

Saito H, Maruyama D, Maeshima AM, et al. Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B‐cell and mantle cell lymphoma [published correction appears in Blood Cancer J. 2017 Nov 3;7(11):e620]. Blood Cancer J 2015;5(10):e362. Published 2015 Oct 23. doi:10.1038/bcj.2015.86 PubMed DOI PMC

Hiddemann W, Barbui AM, Canales MA, et al. Immunochemotherapy with Obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol. 2018;36(23):2395‐2404. doi:10.1200/JCO.2017.76.8960 PubMed DOI

Gaiolla R, Hartley S, Beech A, et al. Extended follow‐up of CD4+ T cell recovery kinetics in a large cohort of patients with B‐cell lymphoproliferative disease treated with rituximab‐bendamustine. Hematol Oncol. 2021;39(1):137‐140. doi:10.1002/hon.2797 PubMed DOI

Laszlo D, Bassi S, Andreola G, et al. Peripheral T‐lymphocyte subsets in patients treated with rituximab‐Chlorambucil combination therapy for indolent NHL. Ann Hematol. 2006;85(11):813‐814. doi:10.1007/s00277-006-0170-9 PubMed DOI

Solman IG, Blum LK, Hoh HY, et al. Ibrutinib restores immune cell numbers and function in first‐line and relapsed/refractory chronic lymphocytic leukemia. Leuk Res. 2020;97:106432. doi:10.1016/j.leukres.2020.106432 PubMed DOI

Eichhorst B, Fink AM, Bahlo J, et al. First‐line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open‐label, randomised, phase 3, non‐inferiority trial. Lancet Oncol. 2016;17(7):928‐942. doi:10.1016/S1470-2045(16)30051-1 PubMed DOI

Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101‐1110. doi:10.1056/NEJMoa1313984 PubMed DOI

Hillmen P, Gribben JG, Follows GA, et al. Rituximab plus chlorambucil as first‐line treatment for chronic lymphocytic leukemia: final analysis of an open‐label phase II study. J Clin Oncol. 2014;32(12):1236‐1241. doi:10.1200/JCO.2013.49.6547 PubMed DOI PMC

Gonzalez‐Rodriguez AP, Contesti J, Huergo‐Zapico L, et al. Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia. Leuk Lymphoma. 2010;51(10):1829‐1836. doi:10.3109/10428194.2010.503820 PubMed DOI

Bojarska‐Junak A, Hus I, Sieklucka M, et al. Natural killer‐like T CD3+/CD16+CD56+ cells in chronic lymphocytic leukemia: intracellular cytokine expression and relationship with clinical outcome. Oncol Rep. 2010;24(3):803‐810. doi:10.3892/or_00000924 PubMed DOI

Giannopoulos K, Schmitt M, Kowal M, et al. Characterization of regulatory T cells in patients with B‐cell chronic lymphocytic leukemia. Oncol Rep. 2008;20(3):677‐682. PubMed

D'Arena G, Rossi G, Minervini MM, et al. Circulating regulatory T cells in "clinical" monoclonal B‐cell lymphocytosis. Int J Immunopathol Pharmacol. 2011;24(4):915‐923. doi:10.1177/039463201102400410 PubMed DOI

Riches JC, Davies JK, McClanahan F, et al. T cells from CLL patients exhibit features of T‐cell exhaustion but retain capacity for cytokine production. Blood. 2013;121(9):1612‐1621. doi:10.1182/blood-2012-09-457531 PubMed DOI PMC

Rissiek A, Schulze C, Bacher U, et al. Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T‐cells in chronic lymphocytic leukemia. Int J Cancer. 2014;135(10):2370‐2379. doi:10.1002/ijc.28884 PubMed DOI

Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 2005;106(6):2018‐2025. doi:10.1182/blood-2005-02-0642 PubMed DOI

Gassner FJ, Weiss L, Geisberger R, et al. Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia. Cancer Immunol Immunother. 2011;60(1):75‐85. doi:10.1007/s00262-010-0920-3 PubMed DOI PMC

Mélet J, Mulleman D, Goupille P, Ribourtout B, Watier H, Thibault G. Rituximab‐induced T cell depletion in patients with rheumatoid arthritis: association with clinical response. Arthritis Rheum. 2013;65(11):2783‐2790. doi:10.1002/art.38107 PubMed DOI